Generic Oncology Sterile Injectable Market Trends, Size, Share, Growth, Analysis, Forecast 2024-2033: Outlook on Competitive Landscape

The generic oncology sterile injectable market size has grown rapidly in recent years. It will grow from $15.68 billion in 2023 to $17.61 billion in 2024 at a compound annual growth rate (CAGR) of 12.3%. The growth in the historic period can be attributed to patent expirations for branded oncology drugs, increasing prevalence of cancer, growing focus on cost-effective healthcare solutions, regulatory support for generic medications, expansion of generic pharmaceutical companies.

The generic oncology sterile injectable market size is expected to see rapid growth in the next few years. It will grow to $27.04 billion in 2028 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to increasing healthcare investments, adoption of biosimilars in oncology, expansion of oncology drug pipelines, rise in global cancer incidence, regulatory pathways for generic sterile injectables. Major trends in the forecast period include development of complex generic oncology drugs, increasing use of advanced manufacturing technologies, rise of personalized medicine in oncology, growing emphasis on biosimilar competition, integration of digital technologies in supply chain management.

Market Overview -
A generic oncology sterile injectable refers to a type of biologic drug with the same active ingredients as the branded version but with only the inactive contents of the drug being different. It is used to treat distinct types of cancer, such as breast, prostate, and colorectal.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=12223&type=smp

Rising Cancer Prevalence Fuels Growth In The Generic Oncology Sterile Injectable Market
The rising prevalence of cancer is expected to propel the growth of the generic oncology sterile injectable market going forward. Cancer is a category of illnesses that can develop in any organ or tissue in the body when aberrant cells proliferate uncontrollably, cross their usual boundaries, and either spread to other organs or invade neighboring body parts. The surge in the prevalence of cancer is driven by smoking, radiation, cancer-causing substances (carcinogens), obesity, and gene mutations. Generic oncology sterile injectable products are used to shrink tumors and stop the growth of cancer cells. For instance, in 2023, according to the American Cancer Society Inc., a US-based non-profit health group, 1.9 million new cancer cases are expected to be diagnosed in the US, an increase compared to more than 1.8 million new cancer cases diagnosed in 2021. Therefore, the rising prevalence of cancer is driving the growth of the oncology sterile injectable market.

Competitive Landscape -
Major companies operating in the generic oncology sterile injectable market report are Pfizer Inc., Johnson & Johnson, Merck & Co Inc., Sanofi S.A., AstraZeneca plc, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Sandoz International GmbH, Fresenius Kabi AG, Sun Pharmaceutical Industries Inc., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Inc., Hikma Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Lupin Limited, Zydus Lifesciences Limited, Nichi-Iko Pharmaceutical Co. Ltd., Biocon Ltd., Jubilant Pharmova Ltd., Gland Pharma Limited, Apotex Inc., Accord Healthcare Ltd.

Product Innovation Drives Momentum In The Generic Oncology Sterile Injectable Market
Product innovation is a key trend gaining popularity in the generic oncology sterile injectable market. Major companies operating in the generic oncology sterile injectable market are developing innovative products to sustain their position in the market. For instance, in July 2022, Dr. Reddy's Laboratories, an India-based pharmaceutical company, launched Bortezomib for injection, a generic version of Velcade. The injection is offered in a single-dose vial with a dosage of 3.5 mg per 10 mL for intravenous or subcutaneous administration and is used for cancer treatment.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/generic-oncology-sterile-injectable-global-market-report

Key Segments -
The generic oncology sterile injectable market covered in this report is segmented -
1) By Product: Chemotherapy, Antimetabolites, Plant Alkaloids, Antitumor Antibiotics, Other Products
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By Disease Indication: Ovarian Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer, Other Indications

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Latest Trending Press Releases: https://www.thebusinessresearchcompany.com/press-release.aspx

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.